TY  - CHAP
M1  - Book, Section
TI  - Transfusion Therapy in Sickle Cell Disease
A1  - Campbell-Lee, Sally A.
A1  - Habibi, Anoosha
A1  - Triulzi, Darrell J.
A2  - Gladwin, Mark T.
A2  - Kato, Gregory J.
A2  - Novelli, Enrico M.
PY  - 2021
T2  - Sickle Cell Disease
AB  - Red  blood  cell  (RBC)  transfusion  has  been  shown  to  be  beneficial  as  part  of  the  treatment  and  management  of  sickle  cell  disease  (SCD),  whether  as  episodic  treatment  for  an  occurrence  of  acute  anemia  or  as  chronic  transfusion  for  prevention  of  stroke  recurrence.  RBCs  transfused  to  patients  with  SCD  should,  at  minimum,  be  from  donors  negative  for  hemoglobin  S  (HbS),  but  patients  may  also  benefit  from  leukoreduction  of  these  blood  components.  As  with  any  transfusion,  RBC  transfusion  should  only  be  used  when  the  benefit  to  the  patient  outweighs  the  risks,  which  in  this  instance  include  transfusion-transmitted  infectious  diseases,  transfusion  reactions,  RBC  alloimmunization,  and  iron  overload.  However,  because  SCD  patients  have  one  of  the  highest  incidences  of  RBC  alloimmunization  among  transfused  patients,  strategies  focused  on  prophylactic  Rh  and  Kell  antigen  matching  and  the  increased  use  of  automated  RBC  exchange  appear  to  mitigate  the  risks  of  RBC  alloimmunization  and  transfusion-related  iron  overload,  respectively.  In  the  event  of  complex  alloimmunization  or  hyperhemolysis,  transfusion  indications  may  be  limited  and  transfusion  may  require  preventative  immunomodulatory  therapies.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - hemonc.mhmedical.com/content.aspx?aid=1179345023
ER  -